VERA · Vera Therapeutics, Inc.
$31.26
-1.02 (-3.14%)
At close · Aug 20
Market Cap
$2.25B
Shares
72.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.26
Open$32.30
Day$30.72–32.30
52W close$21.34–55.67
Avg vol 30d2.0M
Short int15.3M · 21.2% float · 9.4d
Short vol81%
Last earningsNov 5, 2025
DataMay 2021–Aug 2026
Filing10-Q · Aug 10
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−13%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
29%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−23%
trailing
YTD return
−38%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $36 › 200d $39 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.21% of float · ▲ +1.3% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
220 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Free cash flow
$-241.7M
Balance sheet
$279.9M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
29%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $36 › 200d $39 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.21% of float · ▲ +1.3% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
220 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $21
Now $31 · 29%
Range high $56
vs 200-day avg -20%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VERA
this stock
Vera Therapeutics, Inc.
|
$2.25B | -38.3% | — | — | 21.2% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VERA | +8.2% | -14.0% | -23.4% | -2.6% | -38.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +10.2% | -17.3% | -34.5% | -4.7% | -50.1% |
Key facts
CIK
1831828
CUSIP
92337R101
13F (30d)
212 filings
206 filers
Visit website
Investor relations